Kelly Financial Services’s Celldex Therapeutics CLDX Stock Holding History

Kelly Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-46	Closed	-$1.7K	–	225
2024 Q2	$1.7K	Hold	46	–	–	﹤0.01%	604
2024 Q1	$1.93K	Hold	46	–	–	﹤0.01%	604
2023 Q4	$1.82K	Hold	46	–	–	﹤0.01%	590
2023 Q3	$1.27K	Hold	46	–	–	﹤0.01%	596
2023 Q2	$1.56K	Hold	46	–	–	﹤0.01%	568
2023 Q1	$1.66K	Hold	46	–	–	﹤0.01%	540
2022 Q4	$2.05K	Hold	46	–	–	﹤0.01%	505
2022 Q3	$1.29K	Hold	46	–	–	﹤0.01%	549
2022 Q2	$1.24K	Hold	46	–	–	﹤0.01%	538
2022 Q1	$1.57K	Hold	46	–	–	﹤0.01%	544
2021 Q4	$1.78K	Hold	46	–	–	﹤0.01%	552
2021 Q3	$2.48K	Hold	46	–	–	﹤0.01%	494
2021 Q2	$1.54K	Hold	46	–	–	﹤0.01%	535
2021 Q1	$948	Hold	46	–	–	﹤0.01%	553
2020 Q4	$806	Hold	46	–	–	﹤0.01%	527
2020 Q3	$682	Hold	46	–	–	﹤0.01%	510
2020 Q2	$598	Hold	46	–	–	﹤0.01%	526
2020 Q1	$76	Hold	46	–	–	﹤0.01%	560
2019 Q4	$103	Hold	46	–	–	﹤0.01%	545
2019 Q3	$98	Hold	46	–	–	﹤0.01%	537
2019 Q2	$123	Hold	46	–	–	﹤0.01%	486
2019 Q1	$226	Buy	+46	New	+$242	﹤0.01%	464

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kelly Financial Services's CLDX Position: Q3 2024 in Review

Kelly Financial Services sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 46 shares — an estimated $1.7K sold.

Kelly Financial Services first reported a position in CLDX in Q1 2019 and held it in 22 quarters. The position peaked at $2.48K in Q3 2021. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

Kelly Financial Services reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
Kelly Financial Services sold 46 Celldex Therapeutics shares in Q3 2024, an estimated $1.7K.
Kelly Financial Services first reported a position in Celldex Therapeutics in Q1 2019 and held it in 22 quarters.
Kelly Financial Services's Celldex Therapeutics position peaked at $2.48K in Q3 2021.
176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.